Literature DB >> 26155426

Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic.

Franck Housseau1, Nicolas J Llosa1.   

Abstract

The active Th1/CTL immune microenvironment of Microsatellite Instable colorectal cancer (CRC) is counterbalanced by up-regulated expression of multiple immune checkpoints, suggesting that defective mismatch repair may be a biomarker to select CRC patients for treatment with checkpoint inhibitors. This hypothesis is currently being tested in two clinical trials.

Entities:  

Year:  2015        PMID： 26155426      PMCID： PMC4485714          DOI： 10.1080/2162402X.2015.1008858

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

2.  Immunology beats cancer: a blueprint for successful translation.

Authors:  Drew M Pardoll
Journal:  Nat Immunol       Date:  2012-12       Impact factor: 25.606

3.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

4.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

5.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.

Authors:  Marie Tosolini; Amos Kirilovsky; Bernhard Mlecnik; Tessa Fredriksen; Stéphanie Mauger; Gabriela Bindea; Anne Berger; Patrick Bruneval; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

10.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

Authors:  Nienke van Rooij; Marit M van Buuren; Daisy Philips; Arno Velds; Mireille Toebes; Bianca Heemskerk; Laura J A van Dijk; Sam Behjati; Henk Hilkmann; Dris El Atmioui; Marja Nieuwland; Michael R Stratton; Ron M Kerkhoven; Can Kesmir; John B Haanen; Pia Kvistborg; Ton N Schumacher
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544
  10 in total
  5 in total

1.  The colorectal cancer immune paradox revisited.

Authors:  Mihaela Angelova; Pornpimol Charoentong; Hubert Hackl; Z Trajanoski
Journal:  Oncoimmunology       Date:  2015-08-27       Impact factor: 8.110

2.  PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments.

Authors:  Anna Maria Valentini; Federica Di Pinto; Filomena Cariola; Vito Guerra; Gianluigi Giannelli; Maria Lucia Caruso; Michele Pirrelli
Journal:  Oncotarget       Date:  2018-01-12

3.  Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.

Authors:  Lisanne Noordam; Margaretha E H Kaijen; Koen Bezemer; Robin Cornelissen; Lex A P W M Maat; Henk C Hoogsteden; Joachim G J V Aerts; Rudi W Hendriks; Joost P J J Hegmans; Heleen Vroman
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

4.  Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.

Authors:  Kathleen Ducoin; Romain Oger; Linda Bilonda Mutala; Cécile Deleine; Nicolas Jouand; Juliette Desfrançois; Juliette Podevin; Emilie Duchalais; Jonathan Cruard; Houssem Benlalam; Nathalie Labarrière; Céline Bossard; Anne Jarry; Nadine Gervois-Segain
Journal:  Oncoimmunology       Date:  2022-03-09       Impact factor: 8.110

5.  Tumor location impacts immune response in mouse models of colon cancer.

Authors:  Xianda Zhao; Lihua Li; Timothy K Starr; Subbaya Subramanian
Journal:  Oncotarget       Date:  2017-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.